Announced
Completed
Synopsis
Merck, a pharmaceutical company, completed the acquisition of Calporta Therapeutics, a pharmaceutical and therapeutic firm from Avalon Ventures-backed COI Pharmaceuticals for $576m. Calporta develops small molecule agonists of transient receptor potential cation channel, mucolipin subfamily, member 1 (TRPML1) to treat lysosomal storage diseases and neurodegenerative disorders. "This agreement with Merck is an important milestone towards the rapid development of a novel therapeutic approach that could help millions of people with degenerative disorders caused by the toxic accumulation of proteins, fats, or other cellular macromolecules,” Sanford J. Madigan, Calporta CEO.
Show Details & Financials
Sort
Search a database of more than 250,000 verified dealmakers
Receive automated updates on global transactions
Follow the activity, relationships and transactions of top dealmakers
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.